Germany: Rock in the wind or blown into recession?

German economic activity decelerated sharply in H2/2018 and is close to stalling at the outset of 2019. One-off effects like temporary car sector weakness can no longer be blamed. Instead, we find that the weakening of global activity plays a major role for the slowing of the very export-oriented German economy.

Highlights:

  • German economic activity decelerated sharply in H2/2018 and is close to stalling at the outset of 2019.
  • One-off effects like temporary car sector weakness can no longer be blamed. Instead, we find that the weakening of global activity plays a major role for the slowing of the very export-oriented German economy.
  • Moreover, uncertainty arising from the looming risk of US tariffs in general and on EU cars specifically as well as the risk of a crash Brexit is weighing on sentiment.
  • Looking ahead, indicators for domestic activity still look sound. Robust private consumption (thanks to solid wage and employment growth) and a supportive fiscal policy stance amid likely reduced uncertainty will support activity.
  • Germany has plenty of leeway to stimulate activity further. However, we think that the situation is not yet serious enough to trigger additional fiscal policy measures.
  • We expect no quick rebound of growth but look for improvement in H2. In 2019 we see annual growth at only 0.7 %. 

Read the full publication below.

GERMANY: ROCK IN THE WIND OR BLOWN INTO RECESSION?

RELATED INSIGHTS

A (TEMPORARY) COVID ‘LEG DOWN’
The rise in new Covid-19 cases and renewed lockdowns across Europe are casting long shadows over the economic recovery and markets. Yet much more targeted restrictions, a strong Chinese rebound and continued massive fiscal and monetary policy support will keep the second wave’s impact far more muted than in spring.
COVID-19 FACTS & FIGURES
According to the IMF’s Managing Director, strong international cooperation on coronavirus vaccine could speed up the world economic recovery and add $9 trillion to global income by 2025. A WHO trial found that Remdesivir, Hydroxychloroquine, Lopinavir and Interferon have little or no effect on hospitalized Covid-19 patients.
INCORPORATING QUANT SIGNALS INTO EU EQUITY SECTOR/STYLE STRATEGY: MAINTAIN A TILT TO CYCLICALS AND VALUE
We present an update of our proprietary equity valuation tool, based on quant models. It provides indications of over- or undervaluation for different sectors and styles of European equities, which is further enriched by our qualitative analysis.